These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12565917)

  • 1. 103rd ENMC international workshop: designing rational therapy of SMA based on the understanding of its pathophysiology, 18-20 January 2002, Naarden, The Netherlands.
    Vrbová G; Melki J
    Neuromuscul Disord; 2003 Feb; 13(2):173-8. PubMed ID: 12565917
    [No Abstract]   [Full Text] [Related]  

  • 2. 218th ENMC International Workshop:: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016.
    Finkel RS; Sejersen T; Mercuri E;
    Neuromuscul Disord; 2017 Jun; 27(6):596-605. PubMed ID: 28392274
    [No Abstract]   [Full Text] [Related]  

  • 3. 190 th ENMC international workshop: Spinal muscular atrophy with respiratory distress/distal spinal muscular atrophy type 1: 11-13 May 2012, Naarden, The Netherlands.
    van der Pol WL; Talim B; Pitt M; von Au K
    Neuromuscul Disord; 2013 Jul; 23(7):602-9. PubMed ID: 23726377
    [No Abstract]   [Full Text] [Related]  

  • 4. 90th ENMC international workshop: European Spinal Muscular Atrophy Randomised Trial (EuroSMART) 9-10 February 2001, Naarden, The Netherlands.
    Merlini L; Estournet-Mathiaud B; Iannaccone S; Melki J; Muntoni F; Rudnik-Schöneborn S; Topaloglu H; Vita G; Voit T
    Neuromuscul Disord; 2002 Feb; 12(2):201-10. PubMed ID: 11738364
    [No Abstract]   [Full Text] [Related]  

  • 5. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France.
    Mercuri E; Mayhew A; Muntoni F; Messina S; Straub V; Van Ommen GJ; Voit T; Bertini E; Bushby K;
    Neuromuscul Disord; 2008 Nov; 18(11):894-903. PubMed ID: 18818076
    [No Abstract]   [Full Text] [Related]  

  • 6. 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands.
    Bertini E; Burghes A; Bushby K; Estournet-Mathiaud B; Finkel RS; Hughes RA; Iannaccone ST; Melki J; Mercuri E; Muntoni F; Voit T; Reitter B; Swoboda KJ; Tiziano D; Tizzano E; Topaloglu H; Wirth B; Zerres K
    Neuromuscul Disord; 2005 Nov; 15(11):802-16. PubMed ID: 16202598
    [No Abstract]   [Full Text] [Related]  

  • 7. 157th ENMC International Workshop: patient registries for rare, inherited muscular disorders 25-27 January 2008 Naarden, The Netherlands.
    Sárközy A; Bushby K; Béroud C; Lochmüller H
    Neuromuscul Disord; 2008 Dec; 18(12):997-1001. PubMed ID: 18948006
    [No Abstract]   [Full Text] [Related]  

  • 8. 93rd ENMC international workshop: non-5q-spinal muscular atrophies (SMA) - clinical picture (6-8 April 2001, Naarden, The Netherlands).
    Zerres K; Rudnik-Schöneborn S
    Neuromuscul Disord; 2003 Feb; 13(2):179-83. PubMed ID: 12565918
    [No Abstract]   [Full Text] [Related]  

  • 9. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands.
    Finkel R; Bertini E; Muntoni F; Mercuri E;
    Neuromuscul Disord; 2015 Jul; 25(7):593-602. PubMed ID: 26045156
    [No Abstract]   [Full Text] [Related]  

  • 10. Spinal muscular atrophy. 32nd ENMC International Workshop. Naarden, The Netherlands, 10-12 March 1995.
    Munsat T; Davies K
    Neuromuscul Disord; 1996 Mar; 6(2):125-7. PubMed ID: 8664564
    [No Abstract]   [Full Text] [Related]  

  • 11. 38th ENMC International Workshop. Spinal muscular atrophy trial group 10-12 December 1995, Naarden, The Netherlands.
    Neuromuscul Disord; 1996 Aug; 6(4):293-4. PubMed ID: 10712015
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances and challenges in developing a therapy for spinal muscular atrophy.
    Anderton RS; Mastaglia FL
    Expert Rev Neurother; 2015; 15(8):895-908. PubMed ID: 26200127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy.
    Michaud M; Arnoux T; Bielli S; Durand E; Rotrou Y; Jablonka S; Robert F; Giraudon-Paoli M; Riessland M; Mattei MG; Andriambeloson E; Wirth B; Sendtner M; Gallego J; Pruss RM; Bordet T
    Neurobiol Dis; 2010 Apr; 38(1):125-35. PubMed ID: 20085811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How far away is spinal muscular atrophy gene therapy?
    Gillingwater TH; Murray LM
    Expert Rev Neurother; 2015; 15(9):965-8. PubMed ID: 26189552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.
    Passini MA; Bu J; Roskelley EM; Richards AM; Sardi SP; O'Riordan CR; Klinger KW; Shihabuddin LS; Cheng SH
    J Clin Invest; 2010 Apr; 120(4):1253-64. PubMed ID: 20234094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal muscular atrophy: molecular pathophysiology.
    Gendron NH; MacKenzie AE
    Curr Opin Neurol; 1999 Apr; 12(2):137-42. PubMed ID: 10226744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy.
    Lesbordes JC; Cifuentes-Diaz C; Miroglio A; Joshi V; Bordet T; Kahn A; Melki J
    Hum Mol Genet; 2003 Jun; 12(11):1233-9. PubMed ID: 12761038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. At the "junction" of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression.
    Goulet BB; Kothary R; Parks RJ
    Curr Mol Med; 2013 Aug; 13(7):1160-74. PubMed ID: 23514457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.